"Green Light for 'Dream Sales' of 2 Trillion Won... Samsung Biologics Achieves Record-High First Half Sales"

Consolidated Sales of 1.1627 Trillion Won, Individual Sales Also Exceed 1 Trillion
Clear Growth Drivers in Second Half... Partial Operation of 4th Factory in October
Subsidiary Samsung Bioepis's Growth Also Noteworthy

Samsung Biologics Plant 3.

[Asia Economy Reporter Lee Gwan-joo] Samsung Biologics has surpassed 1 trillion KRW in sales for the first time in the first half of the year since its establishment, fueled by the rapid growth of its CMO (Contract Manufacturing Organization) business, signaling a green light for joining the '2 trillion KRW annual sales club.'

According to the bio industry on the 28th, Samsung Biologics' consolidated sales for the second quarter of this year were tentatively estimated at 651.4 billion KRW, with an operating profit of 169.7 billion KRW. For the entire first half, sales reached 1.1627 trillion KRW, and operating profit was 346.1 billion KRW, surpassing 1 trillion KRW for the first time.

This second-quarter performance attracted industry attention as it was the first disclosed result since Samsung Bioepis was officially incorporated as a subsidiary. In April, Samsung Biologics acquired all shares of Samsung Bioepis from Biogen, incorporating it as a consolidated subsidiary. Accordingly, from the acquisition date, Samsung Bioepis' profits and losses have been combined and reported in the consolidated financial results.

Encouragingly, Samsung Biologics' standalone sales for the first half, excluding Samsung Bioepis' results, also exceeded 1 trillion KRW, achieving 1.015 trillion KRW. Since 2019, Samsung Biologics' standalone first-half compound annual growth rate (CAGR) in sales has reached 78.8% over three years.

The bio industry views this earnings announcement as making the achievement of the 'dream sales' milestone of 2 trillion KRW in annual sales more tangible. Among domestic pharmaceutical and bio companies, the first to surpass 2 trillion KRW in annual sales was the diagnostic device company SD Biosensor, which achieved sales of about 2.9 trillion KRW last year. However, this was due to the special demand for diagnostic kits amid the COVID-19 pandemic, and no core bio industry companies such as CDMO (Contract Development and Manufacturing Organization) or biosimilar companies have yet joined the 2 trillion KRW sales club. Samsung Biologics' sales last year were 1.568 trillion KRW, and Celltrion's were 1.9116 trillion KRW.

Samsung Biologics' growth drivers for the second half are also clear. In the first half alone, orders reached 73 for CMO and 95 for CDO (Contract Development Organization). Especially through pre-order activities for Plant 4, which will partially start operations in October, contracts were consecutively signed with global major pharmaceutical companies such as Janssen, Merck, GSK, Eli Lilly, and Novartis. With Plants 1, 2, and 3 all in full operation, Plant 4 (256,000 liters), currently the world's largest under construction, is expected to be a core force for Samsung Biologics to firmly establish itself as the global No. 1 CDMO company.

Samsung Bioepis has also shown continuous sales growth since its founding through product sales revenue in the global market, milestone payments for development achievements, and a solid business portfolio. The autoimmune disease treatment SB4 (Enbrel biosimilar), launched in Europe in 2016, has surpassed the original drug to rank first in local market share, and with the launch of the ophthalmic disease treatment SB11 (Lucentis biosimilar) in the U.S. last month, continuous sales growth is expected in the second half.

This content was produced with the assistance of AI translation services.